Home » London Genetics, Astrimmune to Develop Biomarkers for Pancreatic Cancer Vaccine

London Genetics, Astrimmune to Develop Biomarkers for Pancreatic Cancer Vaccine

Nov 12, 2010

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – London Genetics and Astrimmune today announced a collaboration to identify predictive biomarkers for a pancreatic cancer vaccine being developed by Astrimmune.

The collaboration, being supported with a grant from the UK East Midlands Development Agency, will seek to identify biomarkers predictive of clinical response.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Scan

DNA Defense Not Convincing

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Keep on Brushing

Researchers report that while host genetics influence the oral microbiome, they don't appear to affect cavity-causing microbes, the Economist says.

Panda Gut Seasonality

Pandas' gut microbiomes change as what they eat changes with the seasons, writes Discover's Inkfish blog.

This Week in PLOS

In PLOS this week: comparative genomic study of malaria-linked macaque parasite, search for apple root reference genes, and more.

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.